Etoposide: Four decades of development of a topoisomerase II inhibitor

European Journal of Cancer

Volumn 34, Issue 10, 1998, Pages 1514-1521

  Hande, K R ^a  

^a NONE

Author keywords

Cancer; Etoposide; Etoposide phosphate; History; Pharmacology; Topoisomerase II

Indexed keywords

AMSACRINE; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CHELATING AGENT; DAUNORUBICIN; DISTAMYCIN A; DITERCALINIUM; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ELLIPTINIUM; EPIRUBICIN; ETHIDIUM BROMIDE; ETOPOFOS; ETOPOSIDE; GENISTEIN; IDARUBICIN; INTOPLICINE; MENOGARIL; MERBARONE; MITOXANTRONE; NAPHTHOQUINONE; NITROIMIDAZOLE; PODOPHYLLOTOXIN; RAZOXANE; RUFOCROMOMYCIN; SURAMIN; TENIPOSIDE; UNINDEXED DRUG;

BONE MARROW SUPPRESSION; CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG COST; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; LYMPHOMA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TREATMENT INDICATION;

EID: 0032168167     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00228-7     Document Type: Article

References (76)

1. 1. Liu LF, Chen AY. DNA Topoisomerases: essential enzymes and lethal targets. Ann Rev Pharmacol Toxicol 1994, 34, 191-218.
2. 2. Froelich-Ammon SJ, Osheroff N. Topoisomerase poisons: harnessing the dark side of enzyme mechanisms. J Biol Chem 1995, 270, 21429-21432.
3. 3. Wang JC. Interaction between DNA and E. coli: protein omega. J Mol Biol 1971, 55, 523-533.
4. 4. Gellert M, Mitzuuchi K, O'Dea MH, Nash HA. An enzyme that introduces superhelical turns into DNA. Proc Natl Acad Sci USA 1976, 73, 3872-3876.
5. 5. Slevin M. The clinical pharmacology of etoposide. Cancer 1991, 67, 319-329.
6. 6. King L, Sullivan M. The similarity of the effect of podophyllotoxin and colchicine and their use in the treatment of condylomata acuminata. Science 1946, 104, 244-245.
7. 7. Greenspan E, Lester J, Shear M. Effect of alpha-peltatin, beta-peltatin and podophyllotoxin on lymphoma and other transplanted tumors. J Natl Cancer Inst 1950, 10, 1273-1293.
8. 8. Leiter J, Downing V, Hartwell J, et al. Damage induced in sarcoma 37 with podophyllin, podophyllotoxin, alpha-peltatin, beta-peltatin and quercetin. J Natl Cancer Inst 1950, 10, 1273-1293.
9. 9. Stahelin HF, von Wartburg A. The chemical and biological route from podophyllotoxin glucoside to etoposide: Ninth Cain Memorial Award Lecture. Cancer Res 1991, 51, 5-15.
10. 10. Vogelzang NJ, Raghavan D, Kennedy BJ. VP-16-214 (Etoposide). The mandrake root from Issyk-Kul. Am J Med 1982, 72, 136-144.
11. 11. Johnson DH, Hainsworth JD, Hande KR, Greco FA. Current status of etoposide in the management of small cell lung cancer. Cancer 1991, 67, 231-244.
12. 12. Radice PA, Bunn PA, Ihde DC. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas and other malignancies. Cancer Treat Rep 1979, 63, 1231-1239.
13. 13. Aisner J, Lee EJ. Etoposide: current and future status. Cancer 1991, 67, 215-219.
14. 14. Muggia FM, Russell CA. New chemotherapies for ovarian cancer. Cancer 1991, 67, 225-230.
15. 15. Ajani JA, Ota DM, Jackson DE. Current strategies in the management of locoregional and metastatic gastric carcinoma. Cancer 1991, 67, 260-265.
16. 16. Sledge GW. Etoposide in the management of metastatic breast cancer. Cancer 1991, 67, 266-270.
17. 17. Fleming RA, Miller AA, Stewart CF. Etoposide: an update. Clin Pharmacy 1989, 8, 274-292.
18. 18. Loike JD, Horwitz SB, Grollman AP. Effect of podophyllotoxin and VP-16 on microtubule assembly in vitro and nucleoside transport in HeLa cells. Biochemistry 1976, 15, 5435-5442.
19. 19. Wozniak AJ, Ross WE. DNA damage as a basis for 4-demethyl-epipodophyllotoxicity. Cancer Res 1983, 43, 120-124.
20. 20. Chen GL, Yang L, Rowe TC, et al. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 1984, 259, 13560-13566.
21. 21. Minocha A, Long B. Inhibition of the DNA catenation activity of type II topoisomerase by VP-16-213 and VM 26. Biochem Biophys Res Commun 1984, 122, 165-170.
22. 22. Ross W, Rowe T, Glisson B, et al. Role of topoisomerase II in mediating epipodophyllotoxin-induced cleavage. Cancer Res 1984, 44, 5857-5860.
23. 23. Schwinghammer TL, Reilly M, Rosenfeld CS. Cracking of ABS plastic devices used to infuse undiluted etoposide injection. Am J Hosp Pharm 1988, 45, 1277.
24. 24. Creaven PJ, Allen LM. EPEG, a new antineoplastic epipodophyllotoxin. Clin Pharmacol Ther 1975, 18, 221-226.
25. 25. Hande KR. Etoposide pharmacology. Semin Oncol 1992, 195, 3-9.
26. 26. D'Incalci M, Rossi C, Zucchetti M, et al. Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. Cancer Res 1986, 46, 2566-2571.
27. 27. Creaven PJ, Allen LM. PTG, a new antineoplastic epipodophyllotoxin. Clin Pharmacol Ther 1997, 18, 227-233.
28. 28. Hande KR, Wedlund PJ, Noone RN, et al. Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. Cancer Res 1984, 44, 379-382.
29. 29. Hande KR, Wolff SN, Greco FA, et al. Etoposide kinetics in patients with obstructive jaundice. J Clin Oncol 1990, 8, 1101-1107.
30. 30. Joel SP, Shah R, Clark PI, Slevin ML. Predicting etoposide toxicity: relationship to organ function and protein binding. J Clin Oncol 1996, 14, 257-267.
31. 31. Minami H, Ratain MJ, Ano Y, Shimokata K. Pharmacodynamic modeling of prolonged administration of etoposide. Cancer Chemother Pharmacol 1996, 39, 61-66.
32. 32. Joel SP, Ellis P, O'Bymek, et al. Therapeutic monitoring of continuous etoposide in small cell lung cancer. J Clin Oncol 1996, 14, 1903-1912.
33. 33. Zucchetti M, Pagani O, Torri V. Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer. Clin Cancer Res 1995, 1, 1517-1524.
34. 34. Thompson DS, Hainsworth JD, Hande KR, et al. Prolonged administration of low-dose infusional etoposide in patients with etoposide sensitive neoplasms: a phase I/II study. J Clin Oncol 1993, 11, 1322-1328.
35. 35. Wolff SN, Grosh WW, Prater K, et al. In vitro pharmacodynamic evaluation of VP-16-213 and implications for chemotherapy. Cancer Chemother Pharmacol 1987, 19, 246-249.
36. 36. Drewinko B, Barlogie B. Survival and cycle-progression delay of human lymphoma cells in vitro exposed to VP-16-213. Cancer Treat Rep 1976, 60, 1295-1306.
37. 37. Heck MMS, Hittelman AN, Eamshaw WC. Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc Natl Acad Sci USA, 1988, 85, 1086-1090.
38. 38. Fox ME, Smith PJ. Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumor DNA intercalators mAMSA and mitoxantrone. Cancer Res 1990, 50, 5813-5818.
39. 39. Slevin ML, Clark PI, Joel SP, et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. J Clin Oncol 1989, 7, 1333-1340.
40. 40. Clark PI, Slevin NE, Joel SP, et al. A randomized trial of two etoposide schedules in small cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity. J Clin Oncol 1994, 12, 1427-1435.
41. 41. Hande KR, Krozely MG, Greco FA, et al. Bioavailability of low-dose oral etoposide. J Clin Oncol 1993, 11, 374-377.
42. 42. Joel SP, Clark RI, Heap L, et al. Pharmacological attempts to improve the bioavailability of oral etoposide. Cancer Chemother Pharmacol 1995, 37, 125-133.
43. 43. Leu B, Huang B. Inhibition of intestinal p-glycoprotein and effects on etoposide absorption. Cancer Chemother Pharmacol 1995, 35, 432-436.
44. 44. De Jong RS, Mulder NR, Dijkster Luis D, deVries EG. Review of current clinical experience with prolonged (oral) etoposide in cancer treatment. Anticancer Res 1995, 15, 2319-2330.
45. 45. Hande KR. The importance of drug scheduling in cancer chemotherapy: etoposide as an example. Stem Cells 1996, 14, 18-24.
46. 46. Miller AA, Herndon J, Hollis D, et al. Schedule dependency of 21 day oral versus 3 day intravenous etoposide in combination with intravenous cisplatin in extensive small cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B. J Clin Oncol 1995, 13, 1871-1879.
47. 47. Girling DJ. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small cell lung cancer: a stopped multicenter randomized trial. Lancet 1996, 348, 563-566.
48. 48. Budman DR, Igwemezie LN, Behr J, et al. Phase I evaluation of a water soluble etoposide prodrug, etoposide phosphate, given as a five minute infusion on days 1, 3, 5. J Clin Oncol 1994, 12, 1902-1909.
49. 49. Thompson DS, Greco FA, Miller AA, et al. A phase I trial of etoposide phosphate administered as a daily 30 minute infusion for 5 days. Clin Pharmacol Ther 1995, 57, 499-507.
50. 50. Kaul S, Igwemesie LN, Steward DJ, et al. Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors. J Clin Oncol 1995, 13, 2835-2841.
51. 51. Schacter L. Etoposide phosphate: what, why, where, and how? Semin Oncol 1996, 23(Suppl 6), 1-7.
52. 52. Kreis W, Budman DR, Vinciguerra V, et al. Pharmacokinetic evaluation of high-dose etoposide phosphate after a 2 hour infusion in patients with solid tumors. Cancer Chemother Pharmacol 1996, 38, 378-384.
53. 53. Hainsworth JD, Levitan N, Wampler GL, et al. Phase II randomized study of cisplatin plus etoposide phosphate or etoposide in the treatment of small cell lung cancer. J Clin Oncol 1995, 13, 1436-1442.
54. 54. Doyle JJ, Dezii CM, Sandana A. A pharmacoeconomic evaluation of cisplatin in combination with either etoposide or etoposide phosphate in small cell lung cancer. Semin Oncol 1996, 23(65), 51-60.
55. 55. Sessa C, Zucchetti M, Cerny T, et al. Phase I clinical and pharmacokinetic study of oral etoposide phosphate. J Clin Oncol 1995, 13, 200-209.
56. 56. Chabot GG, Armond JP, Terret C, et al. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study. J Clin Oncol 1996, 44, 2020-2030.
57. 57. Weiss RB. Hypersensitivity reaction. Semin Oncol 1992, 19, 458-477.
58. 58. Pui CH, Riberiro RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphocytic leukemia. N Engl J Med 1991, 325, 1682-1687.
59. 59. Tewey KM, Rowe TC, Yang L, et al. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984, 226, 446-468.
60. 60. Bachur NR, Yu F, Johnson R, et al. Helicase inhibition by arthracycline anticancer agents. Mol Pharmacol 1992, 41, 993-998.
61. 61. Myers CE, McGuire WP, Liss RH, et al. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 1977, 197, 165-169.
62. 62. Minotti G. Adriamycin-dependent release of iron from microsomal membranes. Arch Biochem Biophys 1989, 268, 398-403.
63. 63. Goebel FD, Goldstein D, Goos M, et al. Efficacy and safety of stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. Brit J Cancer 1996, 73, 989-994.
64. 64. Berman E. A review of idarubicin in acute leukemia. Oncology 1993, 7, 91-98.
65. 65. Feig SA, Ames MM, Sather HN, et al. Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group. Med Ped Oncol 1996, 27, 505-514.
66. 66. Lasot WS, deValeriola DL, Piccart MJ. Potential role of oral anthracyclines in older patients with cancer. Drugs & Aging 1994, 4, 393-402.
67. 67. Shan K, Lincott AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996, 125, 47-58.
68. 68. Steinherz LJ, Steinherz PG, Tan CD, et al. Cardiac complications 4 to 20 years after completing anthracycline therapy. JAMA 1991, 266, 1672-1677.
69. 69. Swain SM, Whaley FS, Gerber MD. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1992, 15, 1318-1382.
70. 70. Faulds D, Balfour JA, Chrisp P, Langtry HD. Mitoxantrone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the chemotherapy of cancer. Drugs 1991, 41, 400-449.
71. 71. Benjamin RS. Rationale for use of mitoxantrone in the older patient: cardiac toxicity. Semin Oncol 1995, 22(Suppl 1), 11-13.
72. 72. Cowan JD, Neidhardt J, McClure S, et al. Randomized trial of doxorubicin, bisantrene and mitoxantrone in advanced breast cancer: a Southwest Oncology Group Study. J Natl Cancer Inst 1991, 83, 1077-1084.
73. 73. Stewart DJ, Evans WK, Shepherd FA, et al. Cyclophosphamide and fluorouracil combined with mitoxantrone vs doxorubicin for breast cancer: superiority of doxorubicin. J Clin Oncol 1997, 15, 1897-1905.
74. 74. Posner LE, Dukart G, Goldberg J, et al. Mitoxantrone: an overview of safety and tolerance. Invest New Drugs 1985, 3, 123-132.
75. 75. Sinha BK. Topoisomerase inhibitors: a review of their therapeutic potential in cancer. Drugs 1995, 49, 11-19.
76. 76. Nitiss JL, Beck WT. Antitopoisomerase drug action and resistance. Eur J Cancer 1996, 32A, 958-996.